# A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

> **NCT03494179** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** ICP-022

## Key facts

- **NCT ID:** NCT03494179
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-02
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03494179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03494179, "A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03494179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*